Trial reportClinical research in cardiology : official journal of the German Cardiac Society2008
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Risk assessment based on spectrophotometric signals used in eco-friendly analytical scenarios for estimation of carvedilol and hydrochlorothiazide in pharmaceutical formulation.Scientific reports · 2024Article
- Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis.Frontiers in cell and developmental biology · 2023Review
- Diabetes and treatment of chronic heart failure in a large real-world heart failure population.ESC heart failure · 2022Article
- Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective.Journal of clinical medicine · 2021Review
- Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure.Journal of cardiovascular translational research · 2019Observational
- Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease.Archives of medical science : AMS · 2014Article
- Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure.Yonsei medical journal · 2012Article
- Leptin in anorexia and cachexia syndrome.International journal of peptides · 2012Article
- The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study.Journal of cachexia, sarcopenia and muscle · 2010Article
- Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2010Article
- Insulin resistance and heart failure.Current heart failure reports · 2009Review
- The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure.Wiener klinische Wochenschrift · 2009Article
- Heart failure, aging and beta-blockers: the need for more data on tolerability and efficacy.Clinical research in cardiology : official journal of the German Cardiac Society · 2008Article
- Beta blockers and glucose metabolism in chronic heart failure: friend or foe?Clinical research in cardiology : official journal of the German Cardiac Society · 2008Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia. We aimed to study effects of selective and non-selective beta-blockers on body weight, insulin resistance, plasma concentrations of leptin and resistin in patients with CHF.
methodsTwenty-six non-cachectic beta-blocker-naive patients with CHF were randomized and treated with either carvedilol or bisoprolol. Body weight, plasma concentrations of leptin, resistin, fasting glucose and insulin were measured at baseline and after 6 months of therapy. Insulin resistance was estimated by homeostasis model assessment- estimated insulin resistance (HOMA-IR).
resultsBody weight increased significantly in the carvedilol group (mean change + 2.30 kg, p = 0.023) while it did not change in the bisoprolol group (mean change -0.30 kg, p = 0.623) (ns between groups). Plasma leptin concentration increased only in the carvedilol group (mean change + 4.20 ng/ml, p = 0.019) (ns between groups). Fasting glucose and resistin remained unchanged in both groups. After 6 months, mean plasma insulin concentration changed significantly differently (p = 0.015) in the bisoprolol (mean change +3.1 microU/ml) compared to the carvedilol group (mean change -6.3 microU/ml) and HOMA-IR was consequently higher in the bisoprolol compared to the carvedilol group (5.2 +/- 4.2 vs 2.8 +/- 1.6, p = 0.046).
conclusionThis study found different metabolic effects of carvedilol and bisoprolol in non-cachectic patients with CHF. With unchanged fasting plasma glucose concentration after 6 months of treatment, carvedilol significantly decreased plasma insulin concentration and insulin resistance compared to bisoprolol.
Indexed as
Identifiers
17694376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.